FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, [	D.C. 20549
---------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Troendle August J.</u>						2. Issuer Name and Ticker or Trading Symbol Medpace Holdings, Inc. [ MEDP ]								5. Relationship of Reportir (Check all applicable)  X Director				erson(s) to		
(Last) (First) (Middle) C/O MEDPACE HOLDINGS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 11/27/2023								X	X Officer (give title below) Other (specify below)  CEO					
5375 MEDPACE WAY					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) CINCINNATI OH 45227					X Form filed by One Reporting Person Form filed by More than One Reporting Person															
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication															
		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																		
			l - I	Non-Deriva	_			Ac	quir	ed, D	-	-								
11 11 11 11 11 11 11 11 11 11 11 11 11			2. Transaction Date (Month/Day/Y	ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		" [	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a						6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3		ction(s)			(111511.4)	
Common Stock 11.				11/27/202	23				S <sup>(1)</sup>		25,000	D	\$276.1	(2)	5,664,947		I		By Medpace Investors, LLC <sup>(3)</sup>	
Common Stock			11/28/2023					S <sup>(1)</sup>		21,833	D	\$273.66	5,643,114		13,114	I		By Medpace Investors, LLC <sup>(3)</sup>		
Common Stock					806,643				5,643	D										
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Trans	saction (Instr.	5. Numbe		er 6. Date Ex Expiratior (Month/Da		Expiration	7. Tit Amo Secu Unde Deriv Secu 3 and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  Amount or Number of Title Shares		8. Price of Derivative Security (Instr. 5) Bene Owne Follo Repo Trans (Instr		ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	

## **Explanation of Responses:**

- 1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period.
- 2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$274.26 to \$279.50. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.
- 3. The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- 4. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$272.00 to \$275.91. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

/s/ Stephen P. Ewald, Attorney-in-Fact for August J. 11/29/2023 **Troendle** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.